Who Paid My Doc
Mark Phillips
General Practice Myrtle Creek, OR Medical Doctor
NPI 1275568735 CMS profile 148108
860 North Myrtle Rd, Myrtle Creek, OR 97457
General payments
$746
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Mark Phillips of Myrtle Creek, OR is reported in the CMS Open Payments database as having received $746 across 34 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 75th percentile of General Practice profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
6 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $17 | 1 | |
| 2023 | General | $192 | 10 | |
| 2022 | General | $114 | 6 | |
| 2021 | General | $189 | 9 | |
| 2020 | General | $41 | 3 | |
| 2019 | General | $193 | 5 |
Beside peers
- Mark Phillips
- General Practice median
- Middle half of General Practice
- National median
In program year 2025, general payments to Mark Phillips were reported at $17. Among 4,774 General Practice profiles paid that year, the median was $106 and the middle half received between $35 and $292.
Show as a table
| Year | Mark Phillips | General Practice median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $193 | $107 | $37–$285 | $163 |
| 2020 | $41 | $75 | $25–$213 | $114 |
| 2021 | $189 | $93 | $30–$272 | $132 |
| 2022 | $114 | $103 | $36–$279 | $149 |
| 2023 | $192 | $106 | $34–$276 | $160 |
| 2024 | $0 | $114 | $39–$290 | $164 |
| 2025 | $17 | $106 | $35–$292 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 97 drugsPart D claims
4,050
Drug cost
$240,409
Branded share of claims
21.3%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Xarelto Rivaroxaban | Brand | 100 | $68,419 | |
| Jardiance Empagliflozin | Brand | 24 | $32,208 | |
| Entresto Sacubitril/Valsartan | Brand | 31 | $31,163 | |
| Eliquis Apixaban | Brand | 32 | $27,014 | |
| Myrbetriq Mirabegron | Brand | 18 | $10,764 | |
| Ozempic Semaglutide | Brand | 13 | $10,093 | |
| Basaglar Kwikpen U-100 Insulin Glargine,hum.Rec.Anlog | Brand | 17 | $6,702 | |
| Dexlansoprazole Dr Dexlansoprazole | Brand | 13 | $3,889 | |
| Tamsulosin Hcl | Generic | 103 | $2,002 | |
| Levothyroxine Sodium | Generic | 147 | $1,855 |
The 10 drugs with the highest cost, of 97 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,210 Part D prescribers listed as General Practice; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 29 billing codesPaid by Medicare
$59,697
Medicare patients
142
Services billed
1,396
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 62% | |
| Arthritis | 37% | |
| Cancer | 20% | |
| Ischemic heart disease | 19% | |
| Atrial fibrillation | 19% | |
| Diabetes | 18% | |
| Chronic kidney disease | 15% | |
| Heart failure | 13% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Vaccine for pneumococcal polysaccharide for injection beneath the skin or into muscle, patient 2 years or older 90732 | Office | 16 | 16 | $1,962 |
| Vaccine for influenza for administration into muscle, 0.5 ml dosage 90656 | Office | 77 | 77 | $1,686 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
34 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
General Practice in Oregon
Practitioners in the same specialty and state, ranked by reported value.
All General Practice
Everyone recorded under this specialty, nationwide.
Doctors in Oregon
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.